Proof of concept using a novel ambient storage and transport device: ViveST(TM)

Monitoring HCV viral load is a key diagnostic tool for accessing patient response to direct-acting antiviral therapy. Use of frozen plasma has logistic and cost limitations. Herein, we describe a novel ambient storage and transport device, which can be utilized for management of HCV-infected patient...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2013-01, Vol.18, p.A140-A140
Main Authors: McClernon, A M, Freemen, A B, Yen, C, Carroll, R J, McClernon, D R
Format: Article
Language:English
Subjects:
Hepatitis C virus
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Monitoring HCV viral load is a key diagnostic tool for accessing patient response to direct-acting antiviral therapy. Use of frozen plasma has logistic and cost limitations. Herein, we describe a novel ambient storage and transport device, which can be utilized for management of HCV-infected patients undergoing therapy and provide a global solution for infectious disease testing. HCV infectious plasma (1 ml) was loaded onto ViveST, dried and stored at ambient temperature. Samples were recovered with 1 ml of recovery buffer and analysed using Abbott real time HCV assay (RT). To assess inter and intra precision, specimens with varying viral loads (vl) were analysed in triplicate on three separate runs. ViveST processed samples yielded 95% CI of [lessthan]0.06% inter- and [lessthan]0.05% intra-assay precision with broad analytical measurement range. HCV patient specimens through ViveST and tested produced a similar vl profile as specimens processed with frozen plasma. ViveST device has great potential to offer a global solution for HCV vl access and reduce costs in both developed and developing countries.
ISSN:1359-6535